Key result
PRU-guided intravenous cangrelor achieves 100% technical success without acute ischemic events during pediatric carotid stenting.
Why the study?
Antiplatelet management during endovascular reconstruction of traumatic internal carotid artery injury is challenging in adolescents with polytrauma, unreliable enteral access, or anticipated surgery.
Is PRU-guided intravenous cangrelor feasible for preventing acute in-stent thrombosis and ischemic stroke during endovascular reconstruction of traumatic internal carotid artery injuries in adolescents when oral P2Y12 therapy is unreliable or interrupted?
Case Report (n=3)
No
Is PRU-guided intravenous cangrelor feasible for preventing acute in-stent thrombosis and ischemic stroke during endovascular reconstruction of traumatic internal carotid artery injuries in adolescents when oral P2Y12 therapy is unreliable or interrupted?
This case series demonstrates that off-label, low-dose, PRU-guided intravenous cangrelor is a feasible bridging or adjunctive antiplatelet strategy to prevent acute stent thrombosis during emergent endovascular internal carotid artery reconstruction in adolescents with polytrauma when oral P2Y12 inhibitors are unreliable or interrupted.
Answers are grounded in this paper and cite their sources.
May support PRU-guided cangrelor bridging in select adolescent carotid stenting; hypothesis-generating and requires prospective validation.
Purpose Antiplatelet management during traumatic internal carotid artery (ICA) reconstruction is challenging in adolescents with polytrauma, unreliable enteral access, or anticipated surgery. We describe platelet reactivity unit (PRU)-guided cangrelor use in three adolescents. Methods We retrospectively reviewed three adolescents aged 14–17 years treated during 2024–2025. Injuries included cavernous ICA pseudoaneurysm, penetrating cervical ICA dissection with pseudoaneurysm, and petrous/lacerum ICA occlusion. Reconstruction involved flow diversion, covered stenting, or thrombectomy and angioplasty with carotid stenting. Cangrelor was administered periprocedurally or during interruption of oral P2Y12 therapy at 0.1–0.75 mcg/kg/min, with selective bolus dosing. Dosing and PRU targets were individualized by thrombotic risk, bleeding risk, and procedural needs, using serial PRU and hematologic monitoring. Results Reconstruction was technically successful in all patients. No acute in-stent thrombosis or new ischemic stroke was reported during cangrelor therapy. Hemorrhagic complications included intraventricular hemorrhage after external ventricular drain removal and a postoperative neck hematoma requiring surgical ligation. Polytrauma and concurrent treatments limited attribution to cangrelor. Follow-up imaging demonstrated stent patency, and all patients transitioned to oral dual antiplatelet therapy. One patient was discharged without neurological deficits; two had residual deficits from their presenting injuries. Conclusion PRU-guided cangrelor may be feasible for selected adolescents when oral P2Y12 therapy is unreliable or interrupted. This series cannot establish comparative safety or efficacy. Prospective studies should define dosing, monitoring, and perioperative management; findings should not be generalized to younger children.
No takes yet. Share an insight, caveat, or question.
Trujillo et al. (2026) conducted a case report in Traumatic internal carotid artery (ICA) injury requiring endovascular reconstruction (n=3). Cangrelor was evaluated on Technical success, acute in-stent thrombosis, and new ischemic stroke. PRU-guided intravenous cangrelor achieved 100% technical success with 0% acute in-stent thrombosis or new ischemic stroke in 3 adolescents undergoing traumatic internal carotid artery stenting.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: